News Focus
News Focus
icon url

jtsmgoblue

05/27/19 2:59 AM

#194422 RE: TTTav66 #194420

3T-thanks for sharing. That’s an enlightening article and the emphasis is clearly on a precision medicine type treatment and indirectly on Anavex. Most interesting is that the company comparative financial analysis gives Anavex a CURRENT NPV of 750M. For those non finance types that correlates to a 15 share price. Very clear something amiss with the current market cap (and selling price).

Patience. Anavex will soon have it’s just day!
icon url

Amatuer17

05/27/19 6:11 AM

#194424 RE: TTTav66 #194420

Very nice article
1. A2-73 still is called as P2 R&D drug - not a P3 drug - that shows that it is much farther away than approval
2. Good that M was quoted in the article few times - will give some visibility
icon url

plexrec

05/27/19 9:22 AM

#194435 RE: TTTav66 #194420

"Anavex featured in this story from the healthcare news "--good find TTT--thanks
icon url

LakeshoreLeo1953

05/27/19 9:48 AM

#194440 RE: TTTav66 #194420

Certainly not the assumed S&P attribution, but
an interesting read.
icon url

grich1

05/27/19 12:53 PM

#194479 RE: TTTav66 #194420

Nice Press for Missling and Anavex.

Anavex featured in this story from the healthcare news team at S&P Global Market Intelligence, including quotes throughout from an interview they conducted with Dr. Missling: Failures in Alzheimer's research spur new approaches to drug development
icon url

tradeherpete

05/27/19 2:03 PM

#194487 RE: TTTav66 #194420

http://www.spglobal.com/marketintelligence/en/news-insights/trending/nh1cmgikymvnwfo6kt7h1w2?fbclid=IwAR3qGeE-G5suJE7Zoyz3GKLqeW3jTR7GbikUuiqOdllXPDEZhjw0nxkPC7c



Thanks TTT for the NPV S&P post and others for the analysis. There could be some euphoric moments in our future. More with 2-73 than without. So much good coming our way and so much owed to those that laid down their young lives for USA.
icon url

sage4

05/27/19 2:18 PM

#194489 RE: TTTav66 #194420

Great find! You did it again.

They have found us! Hope we are catching up with the main stream soon.